Cargando…

Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer and the most difficult to predict. When there are no distant metastases, the optimal therapy depends mainly on whether there are malignant lymph nodes in the mediastinum. Given the vigorous debate among speciali...

Descripción completa

Detalles Bibliográficos
Autores principales: Luque, Manuel, Díez, Francisco Javier, Disdier, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727341/
https://www.ncbi.nlm.nih.gov/pubmed/26813400
http://dx.doi.org/10.1186/s12911-016-0246-y
_version_ 1782411950197571584
author Luque, Manuel
Díez, Francisco Javier
Disdier, Carlos
author_facet Luque, Manuel
Díez, Francisco Javier
Disdier, Carlos
author_sort Luque, Manuel
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer and the most difficult to predict. When there are no distant metastases, the optimal therapy depends mainly on whether there are malignant lymph nodes in the mediastinum. Given the vigorous debate among specialists about which tests should be used, our goal was to determine the optimal sequence of tests for each patient. METHODS: We have built an influence diagram (ID) that represents the possible tests, their costs, and their outcomes. This model is equivalent to a decision tree containing millions of branches. In the first evaluation, we only took into account the clinical outcomes (effectiveness). In the second, we used a willingness-to-pay of € 30,000 per quality adjusted life year (QALY) to convert economic costs into effectiveness. We assigned a second-order probability distribution to each parameter in order to conduct several types of sensitivity analysis. RESULTS: Two strategies were obtained using two different criteria. When considering only effectiveness, a positive computed tomography (CT) scan must be followed by a transbronchial needle aspiration (TBNA), an endobronchial ultrasound (EBUS), and an endoscopic ultrasound (EUS). When the CT scan is negative, a positron emission tomography (PET), EBUS, and EUS are performed. If the TBNA or the PET is positive, then a mediastinoscopy is performed only if the EBUS and EUS are negative. If the TBNA or the PET is negative, then a mediastinoscopy is performed only if the EBUS and the EUS give contradictory results. When taking into account economic costs, a positive CT scan is followed by a TBNA; an EBUS is done only when the CT scan or the TBNA is negative. This recommendation of performing a TBNA in certain cases should be discussed by the pneumology community because TBNA is a cheap technique that could avoid an EBUS, an expensive test, for many patients. CONCLUSIONS: We have determined the optimal sequence of tests for the mediastinal staging of NSCLC by considering sensitivity, specificity, and the economic cost of each test. The main novelty of our study is the recommendation of performing TBNA whenever the CT scan is positive. Our model is publicly available so that different experts can populate it with their own parameters and re-examine its conclusions. It is therefore proposed as an evidence-based instrument for reaching a consensus.
format Online
Article
Text
id pubmed-4727341
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47273412016-01-27 Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer Luque, Manuel Díez, Francisco Javier Disdier, Carlos BMC Med Inform Decis Mak Research Article BACKGROUND: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer and the most difficult to predict. When there are no distant metastases, the optimal therapy depends mainly on whether there are malignant lymph nodes in the mediastinum. Given the vigorous debate among specialists about which tests should be used, our goal was to determine the optimal sequence of tests for each patient. METHODS: We have built an influence diagram (ID) that represents the possible tests, their costs, and their outcomes. This model is equivalent to a decision tree containing millions of branches. In the first evaluation, we only took into account the clinical outcomes (effectiveness). In the second, we used a willingness-to-pay of € 30,000 per quality adjusted life year (QALY) to convert economic costs into effectiveness. We assigned a second-order probability distribution to each parameter in order to conduct several types of sensitivity analysis. RESULTS: Two strategies were obtained using two different criteria. When considering only effectiveness, a positive computed tomography (CT) scan must be followed by a transbronchial needle aspiration (TBNA), an endobronchial ultrasound (EBUS), and an endoscopic ultrasound (EUS). When the CT scan is negative, a positron emission tomography (PET), EBUS, and EUS are performed. If the TBNA or the PET is positive, then a mediastinoscopy is performed only if the EBUS and EUS are negative. If the TBNA or the PET is negative, then a mediastinoscopy is performed only if the EBUS and the EUS give contradictory results. When taking into account economic costs, a positive CT scan is followed by a TBNA; an EBUS is done only when the CT scan or the TBNA is negative. This recommendation of performing a TBNA in certain cases should be discussed by the pneumology community because TBNA is a cheap technique that could avoid an EBUS, an expensive test, for many patients. CONCLUSIONS: We have determined the optimal sequence of tests for the mediastinal staging of NSCLC by considering sensitivity, specificity, and the economic cost of each test. The main novelty of our study is the recommendation of performing TBNA whenever the CT scan is positive. Our model is publicly available so that different experts can populate it with their own parameters and re-examine its conclusions. It is therefore proposed as an evidence-based instrument for reaching a consensus. BioMed Central 2016-01-26 /pmc/articles/PMC4727341/ /pubmed/26813400 http://dx.doi.org/10.1186/s12911-016-0246-y Text en © Luque et al. 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Luque, Manuel
Díez, Francisco Javier
Disdier, Carlos
Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title_full Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title_fullStr Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title_full_unstemmed Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title_short Optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
title_sort optimal sequence of tests for the mediastinal staging of non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727341/
https://www.ncbi.nlm.nih.gov/pubmed/26813400
http://dx.doi.org/10.1186/s12911-016-0246-y
work_keys_str_mv AT luquemanuel optimalsequenceoftestsforthemediastinalstagingofnonsmallcelllungcancer
AT diezfranciscojavier optimalsequenceoftestsforthemediastinalstagingofnonsmallcelllungcancer
AT disdiercarlos optimalsequenceoftestsforthemediastinalstagingofnonsmallcelllungcancer